Resources for a Family of Diseases
|
Patients with potentially terminal diseases, who survive months, and sometimes years of misdiagnosis and subsequent treatment, are featured on Mystery Diagnosis, an hour-long cable network show. Published on Thursday, April 5, 2007
|
Most PopularFundraising EventsThe Vasculitis Foundation relies heavily on our local teams to organize and participate in chapter events, act as local area contacts, and organize events. Upcoming EventsOct 11Oct 11Latest newsVasculitis Awareness Week EventsThank you to everyone who participated in Vasculitis Awareness Week! Please click here for a full list of participants. Amgen And Wyeth Statement On The FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) BlockersAmgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) safety announcement regarding opportunistic fungal infections in patients treated with Tumor Necrosis Factor (TNF) blockers [marketed as Remicade® (infliximab), Enbrel® (etanercept), Humira® (adalimumab) and Cimzia® (certolizumab pegol)].
|
About Vasculitis Foundation
The Vasculitis Foundation (VF) is the only international organization for patients with Vasculitis. Founded in 1986, VF provides patients and family members with practical information and coping strategies to live successfully with Vasculitis.
Mission: The Vasculitis Foundation supports and empowers patients through education, awareness and research. Learn more